BridgeMD
A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia
EU CTIS ID: 2024-511474-68-00
What this study is testing
To assess efficacy (MRD response) of belimumab in combination with rituximab/venetoclax in CLL compared to treatment with rituximab/venetoclax alone.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female ≥18 years of age.
- Eastern Cooperative Oncology Group [ECOG] < 3.
- Diagnosis of CLL/SLL established according to iwCLL criteria
- Refractory or relapsed CLL that warrants treatment (according to modified criteria for initiation of therapy (Hallek et al., 2018))
- CLL relapsing after any line of treatment that included radiotherapy, chemotherapy, immunotherapy, or small molecules. Patients who relapse after a previous therapy with venetoclax can be included in the study in case of a late relapse (i.e. >18 months after venetoclax was discontinued.
- Discontinuation of all therapy (including radiotherapy, chemotherapy, immunotherapy, or small molecules) for the treatment of CLL ≥2 weeks before study treatment excluding systemic corticosteroids for symptomatic control.
You likely can't join if
- (Suspicion of) transformation of CLL (i.e. Richter’s transformation, pro-lymphocytic leukemia) or central nervous system (CNS) involvement
- History of prior allogeneic bone marrow or organ transplantation.
- Ongoing immunosuppressive therapy. Subjects may use topical, enteric, or inhaled corticosteroids as therapy for comorbidities and systemic steroids for autoimmune anemia and/or thrombocytopenia. Ongoing use of low-dose systemic corticosteroids (≤5 mg/day of methylprednisolone or equivalent) for rheumatologic conditions is permitted.
- History of primary immunodeficiency
- Concurrent participation in another therapeutic clinical trial.
- History of serious suicide risk including any suicidal behaviour in the last 6 months
See the full eligibility criteria
Who can join
- Male or female ≥18 years of age.
- Eastern Cooperative Oncology Group [ECOG] < 3.
- Diagnosis of CLL/SLL established according to iwCLL criteria
- Refractory or relapsed CLL that warrants treatment (according to modified criteria for initiation of therapy (Hallek et al., 2018))
- CLL relapsing after any line of treatment that included radiotherapy, chemotherapy, immunotherapy, or small molecules. Patients who relapse after a previous therapy with venetoclax can be included in the study in case of a late relapse (i.e. >18 months after venetoclax was discontinued.
- Discontinuation of all therapy (including radiotherapy, chemotherapy, immunotherapy, or small molecules) for the treatment of CLL ≥2 weeks before study treatment excluding systemic corticosteroids for symptomatic control.
- All acute toxic effects of any prior antitumor therapy resolved to Grade ≤1 before treatment (with the exception of alopecia [Grade 1 or 2 permitted], neurotoxicity [Grade 1 or 2 permitted], or bone marrow parameters [any of Grade 1, 2, 3, or 4 permitted]).
- Required baseline laboratory data (within 4 weeks prior to treatment)
- Negative serological Hepatitis B and C test or negative PCR in case of positive serological test without evidence of an active infection, negative HIV test within 6 weeks prior to treatment.
- Written informed consent of the subject
What rules you out
- (Suspicion of) transformation of CLL (i.e. Richter’s transformation, pro-lymphocytic leukemia) or central nervous system (CNS) involvement
- History of prior allogeneic bone marrow or organ transplantation.
- Ongoing immunosuppressive therapy. Subjects may use topical, enteric, or inhaled corticosteroids as therapy for comorbidities and systemic steroids for autoimmune anemia and/or thrombocytopenia. Ongoing use of low-dose systemic corticosteroids (≤5 mg/day of methylprednisolone or equivalent) for rheumatologic conditions is permitted.
- History of primary immunodeficiency
- Concurrent participation in another therapeutic clinical trial.
- History of serious suicide risk including any suicidal behaviour in the last 6 months
- Live vaccination 30 days prior to treatment.
- Hypersensitivity known from medical history to one of the drugs used or their ingredients or to drugs with a similar chemical structure
- Simultaneous participation in another interventional clinical trial (including within the last 4 weeks before inclusion)
- Addictions or other illnesses that do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences
- Pregnant or breastfeeding women
- Early relapse (i.e <18 months) after any line of treatment that included venetoclax.
- Women of childbearing potential, except women who meet the following criteria: A.) post-menopausal (12 months natural amenorrhoea or 6 months amenorrhoea with serum FSH > 40 U/ml) B.) postoperative (6 weeks after bilateral ovarectomy with or without hysterectomy) C.) regular and correct use of a contraceptive method with a Pearl Index < 1% per year, which will have to be continued for up to four months after the discontinuation of the study drug D.) sexual abstinence E.) Vasectomy of the partner
- Male subjects who are able to father a child, except men who meet the following criteria: a. willingness to abstain from heterosexual intercourse or use a protocol-recommended method contraception from the screening visit throughout the study treatment period and for four months following the last dose of study drug b. refrain from sperm donation from screening visit throughout the study treatment period and for 90 days following the last dose of study drug.
- Indications that the subject is unlikely to adhere to the protocol (e.g., lack of compliance)
- IgG < 4 g/L under substitution of immunoglobulins
- Malignancies other than CLL currently requiring systemic therapies
- Evidence of active systemic bacterial (e.g. tuberculosis), fungal, or viral infection (e.g., CMV) at the time of initiation of therapy.
- Confirmed progressive multifocal leukencephalopathy (PML)
- Known history of drug-induced liver injury (DILI), chronic/active hepatitis C (HCV), chronic/active hepatitis B (HBV).
- Requirement of therapy with strong CYP3A4 inhibitors/ inducers or anticoagulant with phenprocoumon (marcumar) or other vitamin Kantagonists
- Active inflammatory bowel disease.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.